Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 68, Issue -, Pages i23-i29Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkt023
Keywords
resistance; antimicrobial; Escherichia; Staphylococcus; Pseudomonas
Funding
- University of Manitoba
- Health Sciences Centre (Winnipeg, Manitoba, Canada)
- Abbott Laboratories Ltd
- Achaogen Inc.
- Affinium Pharmaceuticals Inc.
- Astellas Pharma Canada Inc.
- AstraZeneca
- Bayer Canada
- Cerexa Inc./Forest Laboratories Inc.
- Cubist Pharmaceuticals
- Merck Frosst
- Pfizer Canada Inc.
- Sunovion Pharmaceuticals Canada Inc.
- Medicines Company
- Diagnostic Services of Manitoba, Winnipeg, Canada
Ask authors/readers for more resources
Antimicrobial resistance patterns change over time and longitudinal surveillance studies provide insight into these trends. We sought to describe the important trends in antimicrobial resistance in key pathogens across Canada to provide useful information to clinicians, policy makers and industry, to assist in optimizing antimicrobial therapy, formulary choices and drug development. We analysed longitudinal data from the CANWARD study using a multivariate regression model to control for possible effects of patient demographics on resistance, in order to assess the impact of time on antimicrobial resistance independent of other measured variables. We identified several key trends in common pathogens. In particular, we observed a statistically significant increase in the proportion of Escherichia coli isolates that were resistant to extended-spectrum cephalosporins and fluoroquinolones, an increase in the proportion of Klebsiella pneumoniae isolates that were resistant to extended-spectrum cephalosporins, a reduction in the proportion of Staphylococcus aureus that were methicillin, clindamycin and trimethoprim/sulfamethoxazole resistant, and a reduction in the proportion of Pseudomonas aeruginosa that were fluoroquinolone and gentamicin resistant. Although some of these trends, such as the dramatic increase in fluoroquinolone and cephalosporin resistance in E. coli, can be attributed to the emergence and global spread of resistant clones (e.g. ST131 E. coli), others remain unexplained. However, recognizing these trends remains important to guide changes in empirical antimicrobial therapy and drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available